Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1001 - 1025 of 15720 in total
An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational
Matched Iupac: … methoxy-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]methyl
Matched Description: … An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. …
Matched Categories: … Ergot Alkaloids and Derivatives …
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Matched Iupac: … 13-chloro-2-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-4-azatricyclo[9.4.0.0^{3,8}]pentadeca …
Matched Description: … adult use and liquid formulation for pediatric use. ... Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is ... used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria …
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within...
Approved
Matched Description: … Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently ... through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and ... [F4645] It is also used off-label for the management of chorea associated with Huntington's disease and
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and promote programmed cell death [A31578]. ... , activation, and survival of eosinophils [FDA Label]. ... for recurrent exacerbation and asthma-related hospitalizations [A31579]. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and ... retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization ... many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely target VEGF-A. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and ... Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
Approved
Matched Description: … Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus . This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1,...
Approved
Matched Description: … Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus ... Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and ... other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Approved
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration ... acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and ... ], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed …
Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979....
Approved
Matched Description: … Patent blue is aniline dye and it is one of the most common dyes used. ... Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979. …
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
Approved
Investigational
Matched Description: … Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial ... of action has not been described in the literature, though it positively modulates GABAA and
Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD). This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. Often, patients succumb to this condition by age 30 or...
Approved
Matched Description: … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on ... Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
Approved
Matched Iupac: … 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium …
Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine,...
Approved
Matched Iupac: … 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethan-1-ol …
Matched Description: … piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties. ... Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and ... for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. …
Matched Categories: … Miscellaneous Anxiolytics Sedatives and Hypnotics …
Approved
Investigational
Nutraceutical
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and ... was subsequently approved by the European Commission in April 2022 for both the treatment and prevention …
Terbutaline was first synthesized in 1966 and described in the literature in the late 1960s and early 1970s. It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.
Approved
Matched Description: … and early 1970s. ... Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s …
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of...
Approved
Investigational
Withdrawn
Matched Description: … It has once again been approved and should soon be available on the French and Australian market. …
Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like morphine and oxycodone. Fentanyl's high potency has also...
Approved
Illicit
Investigational
Vet approved
Matched Description: … Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia ... Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and
Matched Categories: … Fentanyl and fentanyl analogues …
Technetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI.. Following intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by...
Approved
Investigational
Matched Description: … infarction (non-reversible defects); and 2) evaluating myocardial function and developing information ... intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by the myocardium, parathyroid, and ... indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and
Matched Categories: … Indicators and Reagents …
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the...
Approved
Matched Description: … The difference in density between the gas-filled bubbles and the blood around them creates an increased ... When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is ... [A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does ... [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …
Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic. Environmental exposure,...
Approved
Matched Description: … , is a major concern for human health and has been the subject of numerous incidents and lawsuits. ... It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic ... and as an inhaled obstetrical analgesic. …
Displaying drugs 1001 - 1025 of 15720 in total